



UK Health
Security
Agency

Vaccine update

Issue 353 • December 2024

END OF YEAR SPECIAL



END OF YEAR SPECIAL • END OF YEAR SPECIAL • END OF YEAR SPECIAL • END OF YEAR SPECIAL

December is traditionally a time for celebration not just Christmas but other cultural and religious holidays such as Hannukah, Rohatsu, Yule and Kwanzaa. Our celebrations often focus on the positive, reflecting on what has been and looking forward to what the coming year may bring.

As we reflect on 2024, and specifically from the perspective of our national immunisation programmes, there have been challenges but also much to be positive about.

Uptake of our routine childhood immunisations has declined, and some programmes are still to fully recover after the pandemic. We have started to see an increase in preventable childhood infections, such as measles, but the NHS responded promptly with an MMR catch-up programme in 2024 which has now been positively evaluated ([weblink 1](#)).

CONTENTS

Measles: a year in review

Please save the date
for the UKHSA's 12th
National Immunisation
Network conference 2025

Attention all ImmForm customers
– Christmas 2024 and New Year
2025 deliveries

Change of vaccine brand for
meningococcal groups
A, C, W and Y vaccination

Introduction of Abrysvo® RSV
vaccine for older adults and during
pregnancy for infant protection


Vaccines for the 2024 to 2025
children's flu programme
supplied by UKHSA

Vaccines and availability

Subscribe to Vaccine update [here](#). Order immunisation publications [here](#).
For centrally-supplied vaccine enquiries, email: vaccinesupply@ukhsa.gov.uk

The algorithm 'Vaccination of individuals with uncertain or incomplete immunisation' can help guide decisions about MMR and other vaccines people may need to bring them up to date with the current UK immunisation schedule if they have missed them or have come to the UK from elsewhere and this can be found at weblink 2.

Through your efforts to vaccinate more people we have now recovered many of the programmes but keeping records up to date when people move into a new area or between areas and services is also really important as it helps to focus activity to improve uptake on those areas and populations who really need additional support.







In 2024 we continued to implement programme changes and new programmes which are benefitting even more people across the life course:

The Shingrix shingles programme for older adults rolled into its second year and has now become established as a routine programme for older adults turning 65, as well as for those turning 70 years of age. As this is an inactivated vaccine more people can benefit from it, including those aged over 50 with a severely weakened immune system who could not previously have the Zostavax vaccine. These people should be given the Shingrix vaccine as a priority to ensure that the most clinically vulnerable are being offered protection against the complications of shingles as soon as possible. The Joint Committee on Vaccination and Immunisation published a full statement on the shingles programme in November 2024, outlining potential further changes to this programme, including recommending expanding the eligibility for those with severe immunosuppression down to age 18, and consideration of including those aged over 80 in future Shingrix programme expansions. These recommendations remain subject to ministerial decisions.

The COVID-19 and seasonal influenza programmes have continued to be delivered, highly effectively and with good uptake, thanks to the efforts of provider colleagues in primary care and pharmacy who have responded admirably to the challenges of changing timescales for these programmes.

2024 continued...

In addition to all this, on 1 September 2024 two new RSV programmes were implemented. The first was for older adults, those turning 75 as a routine year-round programme, with a one-off catch up for those aged 75 to 79. The second is a maternal vaccination programme, given from 28 weeks of pregnancy to protect infants in the first 6 months of life when they are most vulnerable to the serious complications of RSV infection. Implementing these programmes has been particularly challenging due to the very short timescales required to plan and implement them to ensure that those eligible could be called in and become protected before the main RSV season starts. At the point of writing more than 1.2 million vaccines have been given to older adults and nearly 91,000 to pregnant women – this is testament to the fantastic efforts of colleagues in primary care and maternity services who have risen to the challenge and yet again come up trumps despite multiple demands.

We thank you for all that you have done to protect these vulnerable older people and babies ahead of winter.

2025

Looking forward to 2025

2025 is looking equally challenging but also exciting in terms of developments in immunisation. We have recommendations from JCVI to implement a Men B vaccine to prevent Gonorrhea for those at higher risk of infection; an opportunistic Mpox programme for GBMSM; and a varicella programme for children. These statements are currently receiving ministerial consideration and we will have further information on these in 2025.

We are also planning for a wider set of changes to the routine childhood schedule in 2025, which is one of the most significant changes to this programme in decades and will be the subject of one of our special editions early next year.

Delivering the national immunisation programme is never easy but the impact that it has on protecting the population is immense and it is definitely worth it!

It can be challenging and at times the volume of work can seem impossible to deliver. But time after time, thanks to the expertise, commitment and dedication shown by all those who work in immunisation, day after day it gets done!

Thank you for your continuing efforts to deliver the programmes during 2024 from all in the UKHSA Immunisation Programmes and Immunisation & VPD Divisions. We wish you a peaceful festive season and a very happy New Year, and we look forward to supporting you in all you do with our resources and publications in 2025!

I am reminded of a couple of quotes which are particularly pertinent here:

"It always seems impossible until it is done."

– Nelson Mandela

"I'm not telling you it's going to be easy, but I am telling you it's going to be worth it."

– Art Williams


Measles: a year in review

2024 has been a busy year for all those supporting communities experiencing measles outbreaks. Between 1 January and 11 November there were over 2,700 laboratory confirmed cases reported in England, and whilst 47% of cases were in London and 21% in the West Midlands, all regions have been affected. Thankfully there has been a downward trajectory in case numbers since mid-July but small localised outbreaks continue, most recently in the Yorkshire & Humber region and the South-West.

We would like to thank all those who worked so hard on regional and national initiatives to improve vaccine uptake, particularly with vulnerable communities in areas with highest measles activity. A formal evaluation of this catch-up activity can be found at [weblink 1](#).

During the campaign period over 180,000 additional doses of MMR vaccine were given and over 13% of previously unvaccinated children under the age of 5 years were vaccinated with MMR1 compared to baseline. It was very encouraging to find that the largest coverage increases for MMR1 and MMR2 were consistently seen in people from African, Arab, other black and white Gypsy and Irish Traveller ethnic groups, which are all groups with historically lower MMR coverage. Also, for all cohorts for both MMR1 and MMR2, the greatest percentage change in coverage was observed in the most deprived deciles.

2 doses of MMR vaccine remain the best way to protect children from measles, mumps and rubella infection and the key to achieving and maintaining measles control is to sustain efforts to improve MMR vaccination coverage in the routine childhood programme.




MMR for all leaflet

([weblink 11](#))

Printed copies of this leaflet are available to order for free.

Translated versions of this leaflet are free to order in the following languages:

[Bengali](#), [Polish](#), [Romanian](#), [Somali](#), [Ukrainian](#), [Yoruba](#).



Measles – don't let your child catch it flyer and guidance for health centres ([weblink 9](#))

Paper copies of the English flyer are available to order by post, free of charge. Translated versions of the flyer are available in the following languages and accessible formats: [Afrikaans](#), [Arabic](#), [Bengali](#), [Cantonese](#), [Chinese simplified](#), [French](#), [German](#), [Hebrew](#), [Hindi](#), [Italian](#), [Lithuanian](#), [Polish](#), [Portuguese](#), [Romany](#), [Romanian](#), [Spanish](#), [Swahili](#), [Tagalog](#), [Tamil](#), [Turkish](#), [Ukrainian](#), [BSL video](#), [Large print](#).

Would you like to appear in Vaccine update?

As this year draws to a close we would like to once again invite anyone to submit a brief article for vaccine update and thank those who have already been in touch!

Articles should focus on examples of 'How we did it', immunisation best practice at any level. Have you been running accessible clinics? Have you trialled home visits in your local area? Do you have a new way of doing call-recall? We and our readers would love to hear about it.

Submissions should be between 300 and 500 words, ideally with a photograph. Please get in touch at immunisation.website@ukhsa.gov.uk to submit an article or to discuss a future submission.



Please save the date for the UKHSA's 12th National Immunisation Network conference 2025

🕒 **Tuesday June 17 and Wednesday June 18 2025**
 📍 **Honourable Artillery Company, Armoury House, City Road, London EC1Y 2BQ**

The UKHSA's 12th National Immunisation Network (NIN25) conference will focus on current and emerging scientific issues in immunisation and implementation issues relating to the national immunisation programme.

The theme for this year is 'Immunisation: Live long and prosper!' and will focus on data driven developments in vaccines across the life course and their wider economic and societal impact. Experts in the field will update on the data and scientific evidence used to drive improvements to the national programme, and in the evaluation, implementation and uptake of vaccines.

Day 1

Day 1 has a strong scientific focus and will include hot topic sessions on significant exciting new developments and new vaccines used in the routine and selective immunisation programmes.

Day 2

Day 2 has an operational and implementation focus, including sharing of innovative developments and successes in programme delivery.

The NIN25 is a face to face training and professional development meeting provided to bring together the UKHSA National Immunisation team, with colleagues from across the immunisation landscape, including key stakeholders and NHS service providers including wSAIS teams, practice staff, midwives and pharmacists, and others involved in delivering immunisation programmes and in implementing strategies to improve uptake, address health inequalities, maintain and improve immunisation uptake rates in all settings.

The sessions will include panels, debates, subject matter expert presentations, opportunities for discussion and networking.

It will provide all those in the field with up-to-date information on the significant changes that are planned to the immunisation schedule during 2025/26 and the critical work being done to support the continued recovery of uptake of the routine and selective immunisations programmes.



There will be a poster competition and, new for 2025, we will also be launching our own awards for excellence and innovation in immunisation practice – the IMMYs – all of which will be announced at the launch of the website in early January 2025.

Vaccine supply

Routine vaccination programme

Attention all ImmForm customers – Christmas 2024 and New Year 2025 deliveries

Due to the Christmas and New Year Bank Holidays, there will be no deliveries or order processing by Movianto UK on Wednesday 25 and Thursday 26 December 2024, or on Wednesday 1 January 2025. See the table below for your revised order and delivery days, and the additional information for COVID vaccine and offshore customers.

All customers with a standard delivery day of Wednesday, please be aware that after Wednesday 18 December 2024, your next delivery day will be Wednesday 8 January 2025.

All customers should prepare for the break in deliveries and order accordingly. Ensure you have enough room in your fridge for any additional vaccine that you order in advance of this holiday period, bearing in mind the recommendation that only 2 to 4 weeks of vaccine stock should be held locally.

Please be advised that no emergency or out of schedule deliveries can be arranged for ImmForm customers who fail to place their orders in good time.

Christmas and New Year Bank Holidays Wednesday 25 and Thursday 26 December 2024, and Wednesday 1 January 2025			
Standard delivery date	Order cut-off date	Order cut-off time	Notes/Holidays
Monday 16 December 2024	Thursday 12 December 2024	11:55am	N/A
Tuesday 17 December 2024	Friday 13 December 2024	11:55am	N/A
Wednesday 18 December 2024	Monday 16 December 2024	11:55am	Next Wednesday delivery is 8 January
Thursday 19 December 2024	Tuesday 17 December 2024	11:55am	Next Thursday delivery is 2 January
Friday 20 December 2024	Wednesday 18 December 2024	11:55am	N/A
Weekend			
Monday 23 December 2024	Thursday 19 December 2024	11:55am	N/A
Tuesday 24 December 2024	Friday 20 December 2024	11:55am	N/A
Wednesday 25 December 2024	Christmas Day	Closed	No deliveries or order processing
Wednesday 26 December 2024	Boxing Day	Closed	No deliveries or order processing
Friday 27 December 2024	Monday 23 December 2024	11:55am	No frozen COVID vaccine will be delivered today

Table continued on following page.

Subscribe to Vaccine update [here](#). Order immunisation publications [here](#).
For centrally-supplied vaccine enquiries, email: vaccinesupply@ukhsa.gov.uk

Christmas and New Year Bank Holidays Wednesday 25 and Thursday 26 December 2024, and Wednesday 1 January 2025			
Weekend			
Monday 30 December 2024	Tuesday 24 December 2024	11:55am	N/A
Tuesday 31 December 2024	Friday 27 December 2024	11:55am	N/A
Wednesday 01 January 2025	New Year's Day	Closed	No deliveries or order processing
Thursday 02 January 2025	Monday 30 December 2024	11:55am	Scotland orders delivered on 3 January No frozen COVID vaccine will be delivered today
Friday 03 January 2025	Tuesday 31 December 2024	11:55am	N/A
Weekend			
Monday 06 January 2025	Thursday 02 January 2025	11:55am	N/A
Tuesday 07 January 2025	Friday 03 January 2025	11:55am	N/A
Wednesday 08 January 2025	Monday 06 January 2025	11:55am	N/A
Thursday 09 January 2025	Tuesday 07 January 2025	11:55am	N/A

COVID vaccine customers:

- frozen vaccine will not be delivered on either Friday 27 December or Thursday 2 January. Only thawed vaccine will be delivered on those days

Offshore customers:

- Isle of Wight: See the table above for your revised order and delivery days
- Isle of Man: See the table above for your revised order and delivery days
- Jersey: No deliveries will be made to Jersey after Friday 20 December 2024 until Tuesday 7 January 2025. See the table above for your revised order and delivery days
- Guernsey: No deliveries will be made to Guernsey after Friday 20 December 2024 until Tuesday 7 January 2025. See the table above for your revised order and delivery days
- Shetland, Stornoway and Orkney: No deliveries will be made to Shetland, Stornoway or Orkney after Friday 20 December 2024 until Tuesday 7 January 2025. Orders for delivery on Tuesday 7 January 2025 have an earlier order cut-off time and date of 11:55am on Tuesday 31 December 2024

Change of vaccine brand for meningococcal groups A, C, W and Y (MenACWY) vaccination



The vaccine brand used for meningococcal groups A, C, W and Y (MenACWY) vaccination is changing from Nimenrix® to MenQuadfi®. The vaccines are clinically equivalent. Please continue to order and administer Nimenrix® until ImmForm and local stock-holdings deplete.

MenQuadfi® vaccine is now available to order via ImmForm. High-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity.

MenQuadfi® vaccine ordered via ImmForm is supplied as a single dose pack, containing one vial of vaccine and a patient information leaflet (PIL). The pack does not contain a needle or a syringe for administration. Guidance on the choice of needle size can be found in the Green Book ([weblink 3](#)). Needles and syringes should be obtained locally.

MenQuadfi® and Nimenrix® vaccines are packed in different sized cartons. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, the dimensions are:

- MenQuadfi® is 58 x 32 x 45mm (H x W x D)
- Nimenrix® was 57 x 27 x 135mm (H x W x D)

Please add MenQuadfi® to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, please order no more than 2 weeks' worth of stock.

Details about the meningococcal vaccination programme is published in chapter 22 of the Green Book ([weblink 4](#)).

Further details about MenQuadfi® vaccine can be found at [weblink 5](#).

Contact the helpdesk@immform.org.uk for ordering queries.

Introduction of Abrysvo® RSV vaccine for older adults and during pregnancy for infant protection



From 1 September 2024, RSV (respiratory syncytial virus) programmes were introduced for older adults and during pregnancy for infant protection. Please refer to this publication for full details ([weblink 6](#)).

The same RSV vaccine, Abrysvo®, is used for both programmes.

Abrysvo® vaccine is now available to order via ImmForm. Scottish customers should refer to local ordering guidance. High-level ordering controls are in place to reduce the risk of ordering errors only. These are

not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

Abrysvo® vaccine ordered via ImmForm is supplied as a single dose pack, containing one vial of vaccine, diluent for reconstitution and PIL.

Each pack also contains one 25G x 25mm (1") needle. Guidance on the choice of needle size can be found in the Green Book chapter 4 ([weblink 3](#)). If required, other sizes of needles should be obtained locally.

The pack of Abrysvo® vaccine is physically larger than most other vaccines supplied via ImmForm. The vaccine must be stored between 2-8°C. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, each single dose pack measures 73mm x 35mm x 116mm (H x W x D).

When ordering Abrysvo® vaccine, orders should be placed for the ImmForm product that is specific to each RSV protection programme.

Product ordered for the infant RSV protection programme (offered to pregnant women) should not be used for the older adult RSV protection programme and vice versa. Account holders will see two different product lines and should order accordingly (as shown below).

Packs	Brand	↑	Total Items/Doses	Total Pack Price	Action
1	Abrysvo maternal vaccine for infant protection		1	£158.00	Edit Delete
1	Abrysvo vaccine for older adult protection		1	£158.00	Edit Delete

To minimise wastage due to fridge failures, please order no more than 2 weeks' worth of stock.

Details about the RSV vaccination programmes is published in the Green Book chapter 27a ([weblink 7](#)).

Further details about Abrysvo® vaccine can be found in the PIL ([weblink 8](#)).

Contact the helpdesk@immform.org.uk for ordering queries.

Vaccines for the 2024 to 2025 children's flu programme supplied by UKHSA

All flu vaccines for the 2024 to 2025 children's flu programme are available to order by NHS providers in England via ImmForm.

UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Expiry dates for all batches of Fluenz[®] issued for the 2024 to 2025 children's flu programme

Batch numbers and associated expiry dates of all batches of Fluenz[®] issued this season are set out in the table below. Some batches are now past or approaching the end of their shelf life so please remember to check expiry dates before administering.

Ensure that expired stock is disposed of in line with local policies. Any disposed stock should be recorded through the ImmForm stock incident page.

Batch number	Expiry date	Batch number	Expiry date
WH2527	Tuesday 10 December 2024	WK2077	Monday 06 January 2025
WH2527B	Tuesday 10 December 2024	WK3406	Monday 13 January 2025
WH2544	Wednesday 11 December 2024	WK3410	Monday 13 January 2025
WH2544B	Wednesday 11 December 2024	WL2038	Monday 20 January 2025
WH2545B	Monday 16 December 2024	WL2038B	Monday 20 January 2025
WH2546B	Tuesday 17 December 2024	WL2039	Monday 27 January 2025
WH2547	Wednesday 18 December 2024	WL2039B	Monday 27 January 2025
WH2547B	Monday 23 December 2024	WL2041	Tuesday 28 January 2025
WJ2622B	Monday 23 December 2024	WL2040	Monday 03 February 2025
WJ2150	Tuesday 24 December 2024	WL2040B	Monday 03 February 2025
WJ2622	Tuesday 24 December 2024	WL2522	Monday 10 February 2025
WJ2623	Monday 30 December 2024	WL2522B	Monday 10 February 2025
WK2074	Monday 30 December 2024	WL2688	Monday 17 February 2025
WK2074B	Tuesday 31 December 2024	WL2688B	Monday 17 February 2025
		WM2017	Monday 03 March 2025

Vaccines and availability

The 2 vaccines that are available and the groups that these vaccines should be ordered for are set out in the table below.

Vaccine	Manufacturer	Available to order for
Fluenz® (LAIV)	AstraZeneca	All children from 2 years of age to school year 11; and Children in clinical risk groups aged 2 to <18 years*
Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc)	Seqirus	Children in clinical risk groups aged 6 months to <2 years All other eligible** children aged 2 to <18 years for whom LAIV is unsuitable

*Unless LAIV clinically contraindicated or otherwise unsuitable

** Children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to <18 years

LAIV ordering information for General Practice

GPs are able to place one order and receive one delivery of LAIV per week.

All GP practices are able to order 2 packs (20 doses) per week.

Requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period. Requests for additional vaccine should be sent to the helpdesk (helpdesk@immform.org.uk) and should be sent in good time before your order cut-off. Out of schedule deliveries will be by exception only.

LAIV ordering information for school-age providers

School providers are able to place 2 orders and receive 2 deliveries of LAIV per week, to assist in the management of vaccine volumes required across limited storage space at delivery points.

This operates on a 48-hour delivery schedule requiring the order to be placed before the 11.55am cut-off 2 working days before the required delivery day. The table below illustrates the respective delivery days versus ordering days.

Please note the bank holiday schedule when placing orders for delivery over the Christmas period.

Order day (before 11:55am cut-off)	Delivery day
Monday	Wednesday
Tuesday	Thursday
Wednesday	Friday
Thursday	Monday
Friday	Tuesday

Customers must ensure that the point of delivery will be open and staffed between 9am and 5pm on the delivery day when placing orders.

Please note that this 48-hour delivery schedule does not affect the routine ordering and delivery schedule of any other vaccines (including inactivated flu vaccines) ordered from ImmForm and is applicable to Fluenz® (LAIV) only.

A default weekly ordering cap of 450 packs (4,500 doses) per week is in place for school provider accounts.

Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk.

Inactivated flu vaccine ordering

The Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc) is available to order, in a single dose pack, for:

- children in clinical risk groups aged from 6 months to less than 2 years old
- children aged from 2 to <18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
- healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls are also in place for this vaccine as follows:

- for GPs, there is a cap of 10 doses/packs per week
- for school-age providers, there is a cap of 450 doses/packs per week

All influenza vaccines for the 2024 to 2025 season

Information on all influenza vaccines that have been marketed in the UK for the 2024 to 2025 season are available in the flu collection on GOV.UK ([weblink 10](#)).

The impact of changes to opening hours on routine vaccine deliveries

Please consider temporary changes to opening times when placing ImmForm orders. If you are aware of a scheduled site closure, please refrain from placing an order for that date. In case of a one-off closure, consider rescheduling your order for the week before or after. This approach will contribute to improved overall efficiencies and enhance delivery performance for the benefit of all customers.

It is not possible to accommodate one-off changes to delivery days. Customers should report long-term changes to the days and times when they can accept deliveries, such as routine training days and closures, by contacting Movianto UK Customer Care (moviantouk.nhscc@movianto.com; 01234 587207). This should not be used to report short-term changes due to absence or holidays.

DTaP/IPV/Hib/HepB vaccine ordering

Supplies of DTaP/IPV/Hib/HepB vaccines Infanrix hexa® and Vaxelis® are available for the routine infant primary immunisations programme.

Orders for Infanrix hexa® remain unrestricted. Customers in England and Wales may order up to 20 packs of Vaxelis® per ImmForm account per week. Customers in Scotland should refer to their local ordering restrictions. Providers should not order more than 2 weeks' worth of stock to minimise wastage due to fridge failures. For assistance, please contact the ImmForm Helpdesk at helpdesk@immform.org.uk.

The European Union (EU) Falsified Medicines Directive (FMD) will not apply in Northern Ireland from 1 January 2025

From 1 January 2025, the European Union (EU) Falsified Medicines Directive (FMD) will no longer apply in Northern Ireland. The Windsor Framework agreement removes any EU FMD packaging, labelling and barcode requirements for medicines distributed in Northern Ireland.

From 1 January 2025, customers across the UK will no longer have access to the EU database to verify or decommission unique identifier (UI) codes and will be unable to scan FMD barcodes in at any stage of the supply chain.

From 1 January 2025, customers in Northern Ireland are not required, nor will they have the capability, to verify medicines using the European Medicines Verification System (EMVS SecurMed).

MMR vaccine ordering

M-M-RvaxPro vaccine should be ordered for all MMR vaccinations, unless a patient requires a porcine gelatine-free MMR vaccine. ImmForm customers in England and Wales may order M-M-RvaxPro vaccine without restriction.

In addition, ImmForm customers in England and Wales may order up to 10 porcine gelatine-free Priorix vaccines per account per week.

ImmForm customers in Scotland should refer to their local ordering restrictions.

Both MMR vaccines may only be ordered for outbreak purposes when this is part of a national catch-up campaign.

Vaccine supply

Non-routine vaccine supply

HEPATITIS A VACCINE

Adult

- GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available
- Sanofi Pasteur: Avaxim PFS singles are currently available. Avaxim packs of 10 is currently available
- MSD: VAQTA Adult is available

Paediatric

- GSK: supply of Havrix Paediatric singles and packs of 10 are currently available
- MSD: VAQTA Paediatric is available
- Sanofi Pasteur: Avaxim Junior singles are currently available

HEPATITIS B VACCINE

Adult

- GSK: Engerix B PFS singles and packs of 10 are currently available
- GSK: supply of Fendrix is currently available
- MSD: HBVAXPRO 10 µg is available
- MSD: HBVAXPRO 40 µg is available
- Valneva: PreHevbri is not available

Paediatric

- GSK: supplies of Engerix B Paediatric singles is currently available
- MSD: HBVAXPRO 5µg is available

COMBINED HEPATITIS A AND B VACCINE

- GSK: Twinrix Adult singles and packs of 10 are available
- GSK: Twinrix Paediatric is currently available
- GSK: Ambirix is available

COMBINED HEPATITIS A AND TYPHOID VACCINE

- Sanofi Pasteur: Viatim is now a discontinued product and no longer available for sale

TYPHOID VACCINE

- Sanofi Pasteur: Typhim singles and packs of 10 are available
- Patientric: Vivotif is available

RABIES VACCINE

- Valneva; Rabipur is currently available
- Sanofi Pasteur: Verorab is currently available

PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV)

- MSD: supply of Pneumovax 23 (PPV23) PFS is available

PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV)

- Pfizer: Prevenar 13 is currently available
- MSD: Vaxneuvance is currently available

VARICELLA ZOSTER VACCINE

- GSK: VARILRIX is currently available
- MSD: VARIVAX is available
- MSD: ZOSTAVAX is a discontinued product

DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE

- Sanofi Pasteur: Revaxis is available

DIPHTHERIA, TETANUS, PERTUSSIS (ACELLULAR) AND POLIOMYELITIS (INACTIVATED) VACCINE

- GSK: supply of Boostrix-IPV is currently available
- Sanofi Pasteur: Repevax is currently available

MMR

- MSD: MMR Vaxpro is currently available
- GSK: Priorix is currently available

MENINGITIS ACWY VACCINE

- GSK: Menveo is currently available
- Pfizer: Nimenrix is currently available
- Sanofi Pasteur: MenQuadfi is available

YELLOW FEVER

- Sanofi Pasteur: Stamaril is available

HUMAN PAPILLOMAVIRUS VACCINE

- MSD: GARDASIL has been discontinued
- MSD: Gardasil 9 is currently available
- GSK: Cervarix has been discontinued

CHOLERA VACCINE

- Valneva: Dukoral is available
- Patientric: Vaxchora is available

JAPANESE ENCEPHALYTIS VACCINE

- Valneva: Ixiaro is available

MENINGOCOCCAL GROUP B VACCINE

- GSK: Bexsero is currently available

DIPHTHERIA, TETANUS, PERTUSSIS, HIB VACCINE AND POLIOMYELITIS

- GSK: Infanrix IPV+Hib is currently available

HIB + MENINGOCOCCAL GROUP C COMBINED VACCINE

- GSK: Menitorix is currently available

LIVE ATTENUATED ROTAVIRUS VACCINE

- GSK: Rotarix is currently available

HERPES ZOSTER VACCINE

- GSK: Shingrix is currently available

DIPHTHERIA, TETANUS AND PERTUSSIS

- Sanofi Pasteur: Adacel is available to order without restrictions

DENGUE TETRAVALENT VACCINE

- Takeda: Qdenga is currently available

RESPIRATORY SYNCYTIAL VIRUS VACCINE

- Pfizer: Abrysvo is currently available

Weblinks

- | | |
|------------|---|
| Weblink 1 | www.gov.uk/government/publications/evaluation-of-vaccine-uptake-during-the-2023-to-2024-mmr-catch-up-campaigns-in-england/evaluating-the-impact-of-national-and-regional-measles-catch-up-activity-on-mmr-vaccine-coverage-in-england-2023-to-2024 |
| Weblink 2 | www.gov.uk/government/publications/vaccination-of-individuals-with-uncertain-or-incomplete-immunisation-status |
| Weblink 3 | assets.publishing.service.gov.uk/media/5a7afc62e5274a34770e88e5/Green-Book-Chapter-4.pdf |
| Weblink 4 | assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf |
| Weblink 5 | www.medicines.org.uk/emc/product/12818/smpc |
| Weblink 6 | www.gov.uk/government/publications/respiratory-syncytial-virus-rsv-vaccination-programmes-letter/introduction-of-new-nhs-vaccination-programmes-against-respiratory-syncytial-virus-rsv |
| Weblink 7 | www.gov.uk/government/publications/respiratory-syncytial-virus-the-green-book-chapter-27a |
| Weblink 8 | www.medicines.org.uk/emc/product/15309/smpc |
| Weblink 9 | www.healthpublications.gov.uk/ViewProduct.html?sp=Smeaslesdontletyourchildcatchitflyerforschools-465 |
| Weblink 10 | www.gov.uk/government/publications/influenza-vaccines-marketed-in-the-uk |
| Weblink 11 | www.healthpublications.gov.uk/ViewProduct.html?sp=Smmrvaccinewhichhelpsprotectagainstallthree-488 |